Literature DB >> 1284355

[Changed levels of substance P and somatostatin in HIV-positive children].

C Azzari1, M E Rossi, M Resti, A L Caldini, L Lega, L Galli, E Fico, A Vierucci.   

Abstract

Substance P (sP) and Somatostatin (SOM), so as other neuropeptides can modulate neurologic and immunologic functions. sP has been described to enhance both in vitro and in vivo immunoglobulin synthesis. On the contrary, SOM has an inhibitory effect on the same activity. The modulating effect is more evident on IgA isotype. Hypergammaglobulinemia and in particular high levels of IgA is a common finding in pediatric AIDS and an imbalance among regulatory effects of neuropeptides might be suggested. In order to evaluate the plasma levels of sP in pediatric AIDS we studied 15 children with HIV infection (status P2), 10 seronegative children born to HIV positive mothers and 10 healthy children of the same age. All the HIV positive children had high plasma levels of IgG and IgA. The plasma level of sP was extremely higher in HIV positive children while no significant difference was found between seronegative children born to HIV positive mothers and healthy children. SOM was decreased in HIV positive children when compared to control groups but a significant difference was not reached. It might be supposed that HIV infection, through a dysregulation among neuropeptides interferes on immune functions and in particular on IgA synthesis. On the other hand it might be suggested that the imbalance between sP and SOM depends on the viral infection of immune cells since it has been demonstrated that SOM and other neuropeptide are synthesized by lymphoid tissue. Further studied relevance of neuropeptide disorders in pediatric AIDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284355

Source DB:  PubMed          Journal:  Pediatr Med Chir        ISSN: 0391-5387


  8 in total

1.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.

Authors:  Jeffrey A Rumbaugh; Joseph Steiner; Ned Sacktor; Avindra Nath
Journal:  Futur HIV Ther       Date:  2008

3.  Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay.

Authors:  W P Fehder; W Z Ho; D E Campbell; W W Tourtellotte; L Michaels; J R Cutilli; M Uvaydova; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.

Authors:  Lynnae Schwartz; Sergei V Spitsin; John Meshki; Florin Tuluc; Steven D Douglas; John H Wolfe
Journal:  J Neurovirol       Date:  2013-06-14       Impact factor: 2.643

5.  Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells.

Authors:  Tzong-Shi Lu; Hava Karsenty Avraham; Seyha Seng; Souvenir D Tachado; Henry Koziel; Alexandros Makriyannis; Shalom Avraham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

6.  Disturbed immunoregulatory properties of the neuropeptide substance P on lymphocyte proliferation in HIV infection.

Authors:  M J Covas; L A Pinto; R M Victorino
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.

Authors:  Xu Wang; Steven D Douglas; Li Song; Yan-Jian Wang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2008-07-25       Impact factor: 4.147

8.  Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.

Authors:  Xu Wang; Steven D Douglas; Jian-Ping Lai; Florin Tuluc; Pablo Tebas; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-12       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.